FDA’s Candid Overview Of Cosmetics Regime Signals Support For Reform Bill
This article was originally published in The Rose Sheet
In a letter to California Democratic Senator Dianne Feinstein, FDA’s Acting Associate Commissioner for Legislation Dayle Cristinzio acknowledges the agency’s limited insight into cosmetic formulations and safety information, which makes it a struggle to respond to issues as they arise. Feinstein characterizes the letter as an admission of current system failings and a nod of support for her Personal Care Products Safety Act.
You may also be interested in...
Under the draft FDA Cosmetic Safety and Modernization Act, a product could be deemed adulterated "regardless of whether it is known which particular substance or substances may render the cosmetic injurious." EAS Consulting Group's John Bailey offers his perspective on the provision and the overall bill in an exchange with the Rose Sheet.
ICMAD's recent regulatory workshop offered perspective from FDA's Linda Katz and industry experts on the inspection process for cosmetics facilities under current law. It's clear that FDA inspections can be an ordeal, but that would pale in comparison to challenges that could arise under the proposed Personal Care Products Safety Act.
The Rose Sheet’s coverage of FDA’s warning letter crackdown and data sharing produced some of its most-read stories of 2016, based on online analytics. Legislative proposals and cosmetic safety issues in the US mainstream factored in the agency’s transparency work, a situation that may not repeat in the new year.